Chromatography and Mass Spectrometry Section, Central Laboratory of Analyses, IRCCS Istituto Giannina Gaslini, Genoa, Italy.
Infectious Disease Unit, IRCCS Istituto Giannina Gaslini, Genova, Italy.
J Pharm Biomed Anal. 2020 Jul 15;186:113273. doi: 10.1016/j.jpba.2020.113273. Epub 2020 Mar 26.
The accurate measurement of plasma levels of antibiotics is crucial for the individualization of antimicrobial therapies based on PK/PD strategies. In this paper we describe a new rapid and simple LC-MS/MS platform for quantifying 14 antibiotics (amikacin, amoxicillin, ceftazidime, ciprofloxacin, colistin, daptomycin, gentamicin, linezolid, meropenem, piperacillin, teicoplanin, tigecycline, tobramycin and vancomycin) and a beta-lactamase inhibitor (tazobactam) starting from 50 μL plasma samples.
Analyses were performed on a Thermo Scientific™ Ultimate™ 3000 LC system (Thermo Fisher Scientific, Milan, Italy) coupled to a Thermo Scientific™ TSQ Quantiva™ Triple Quadrupole mass spectrometer. After fast protein precipitation protocols and addition of deuterated internal standards, samples were subjected to a fast HPLC gradient separation and the 15 drugs were quantified using multiple reaction monitoring of specific transitions over a wide range of concentrations. The suitability of the assay for TDM was tested on plasma samples derived from pediatric patients under treatment with one or more antibiotics.
The overall turnaround time of the assay was 20 min. The assay was validated following EMA guidelines for bioanalytical method validation and showed excellent accuracy (ranging from 85.3 and 112.7) and reproducibility (ranging from 1.3 to 9.7) as well as the absence of matrix effects (<15 %) for all the drugs tested. The lower limits of quantifications were between 0.1 and 2 mg/L. the recovery rate exceeded 85 % for all the drug tested. Stability was evaluated in different conditions thus allowing the setting up of reliable operative procedures.
This work provides a LC-MS/MS platform validated for clinical use for a rapid quantification of a broad spectrum of drugs having different chemical characteristics in a small volume of plasma and is suitable for real-time TDM-guided personalization of antimicrobial treatment in critically ill patients.
准确测量抗生素的血浆水平对于基于 PK/PD 策略的个体化抗菌治疗至关重要。本文介绍了一种新的快速简便的 LC-MS/MS 平台,用于定量分析 14 种抗生素(阿米卡星、阿莫西林、头孢他啶、环丙沙星、黏菌素、达托霉素、庆大霉素、利奈唑胺、美罗培南、哌拉西林、替考拉宁、替加环素、妥布霉素和万古霉素)和一种β-内酰胺酶抑制剂(他唑巴坦),起始血浆样本量为 50μL。
分析在 Thermo Scientific™Ultimate™3000 LC 系统(赛默飞世尔科技,意大利米兰)上进行,与 Thermo Scientific™TSQ Quantiva™三重四极杆质谱仪联用。经过快速蛋白沉淀方案和加入氘代内标后,样品进行快速 HPLC 梯度分离,通过特定转换的多重反应监测在宽浓度范围内定量 15 种药物。该测定法适用于治疗中使用一种或多种抗生素的儿科患者的 TDM,通过测试血浆样本进行验证。
该测定法的总周转时间为 20 分钟。该测定法根据 EMA 生物分析方法验证指南进行验证,显示出极好的准确性(范围为 85.3%至 112.7%)和重现性(范围为 1.3%至 9.7%),以及所有测试药物的基质效应小于 15%。定量下限在 0.1 至 2mg/L 之间。所有测试药物的回收率均超过 85%。在不同条件下评估了稳定性,从而可以建立可靠的操作程序。
本研究提供了一种经过验证可用于临床的 LC-MS/MS 平台,用于快速定量分析具有不同化学特性的广谱药物,在小体积血浆中,适用于危重症患者实时 TDM 指导的个体化抗菌治疗。